Literature DB >> 30772369

Parkinson's disease and pain: Modulation of nociceptive circuitry in a rat model of nigrostriatal lesion.

Roberta A Domenici1, Ana Carolina P Campos1, Soraya T Maciel1, Miriã B Berzuino1, Marina S Hernandes2, Erich T Fonoff3, Rosana L Pagano4.   

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder that causes progressive dysfunction of dopaminergic and non-dopaminergic neurons, generating motor and nonmotor signs and symptoms. Pain is reported as the most bothersome nonmotor symptom in PD; however, pain remains overlooked and poorly understood. In this study, we evaluated the nociceptive behavior and the descending analgesia circuitry in a rat model of PD. Three independent experiments were performed to investigate: i) thermal nociceptive behavior; ii) mechanical nociceptive behavior and dopaminergic repositioning; and iii) modulation of the pain control circuitry. The rat model of PD, induced by unilateral striatal 6-hydroxydopamine (6-OHDA), did not interfere with thermal nociceptive responses; however, the mechanical nociceptive threshold was decreased bilaterally compared to that of naive or striatal saline-injected rats. This response was reversed by apomorphine or levodopa treatment. Striatal 6-OHDA induced motor impairments and reduced dopaminergic neuron immunolabeling as well as the pattern of neuronal activation (c-Fos) in the substantia nigra ipsilateral (IPL) to the lesion. In the midbrain periaqueductal gray (PAG), 6-OHDA-induced lesion increased IPL and decreased contralateral PAG GABAergic labeling compared to control. In the dorsal horn of the spinal cord, lesioned rats showed bilateral inhibition of enkephalin and μ-opioid receptor labeling. Taken together, we demonstrated that the unilateral 6-OHDA-induced PD model induces bilateral mechanical hypernociception, which is reversed by dopamine restoration, changes in the PAG circuitry, and inhibition of spinal opioidergic regulation, probably due to impaired descending analgesic control. A better understanding of pain mechanisms in PD patients is critical for developing better therapeutic strategies to improve their quality of life.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dopaminergic agonists; Enkephalin; GABA; Pain; Parkinson's disease; Periaqueductal gray; Spinal cord

Year:  2019        PMID: 30772369     DOI: 10.1016/j.expneurol.2019.02.007

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  9 in total

Review 1.  Potential of animal models for advancing the understanding and treatment of pain in Parkinson's disease.

Authors:  Yazead Buhidma; Katarina Rukavina; Kallol Ray Chaudhuri; Susan Duty
Journal:  NPJ Parkinsons Dis       Date:  2020-01-06

2.  Evaluation of betulinic acid effects on pain, memory, anxiety, catalepsy, and oxidative stress in animal model of Parkinson's disease.

Authors:  M Abrishamdar; Yaghoob Farbood; A Sarkaki; M Rashno; M Badavi
Journal:  Metab Brain Dis       Date:  2022-06-16       Impact factor: 3.584

Review 3.  Pain in Parkinson's disease and the role of the subthalamic nucleus.

Authors:  Abteen Mostofi; Francesca Morgante; Mark J Edwards; Peter Brown; Erlick A C Pereira
Journal:  Brain       Date:  2021-06-22       Impact factor: 13.501

Review 4.  The Noradrenergic System in Parkinson's Disease.

Authors:  Elena Paredes-Rodriguez; Sergio Vegas-Suarez; Teresa Morera-Herreras; Philippe De Deurwaerdere; Cristina Miguelez
Journal:  Front Pharmacol       Date:  2020-04-08       Impact factor: 5.810

5.  Unraveling the Role of Astrocytes in Subthalamic Nucleus Deep Brain Stimulation in a Parkinson's Disease Rat Model.

Authors:  Ana Carolina Pinheiro Campos; Daniel Seicho Kikuchi; Amanda Faure Nardini Paschoa; Mayra Akemi Kuroki; Erich Talamoni Fonoff; Clement Hamani; Rosana Lima Pagano; Marina Sorrentino Hernandes
Journal:  Cell Mol Neurobiol       Date:  2020-01-14       Impact factor: 5.046

Review 6.  Potential of animal models for advancing the understanding and treatment of pain in Parkinson's disease.

Authors:  Yazead Buhidma; Katarina Rukavina; Kallol Ray Chaudhuri; Susan Duty
Journal:  NPJ Parkinsons Dis       Date:  2020-01-06

7.  D2 receptor activation relieves pain hypersensitivity by inhibiting superficial dorsal horn neurons in parkinsonian mice.

Authors:  Dong-Liang Tang; Yi-Wen Luan; Chun-Yi Zhou; Cheng Xiao
Journal:  Acta Pharmacol Sin       Date:  2020-07-21       Impact factor: 6.150

8.  Is dopaminergic medication dose associated with self-reported bruxism in Parkinson's disease? A cross-sectional, questionnaire-based study.

Authors:  M C Verhoeff; M Koutris; M K A van Selms; A N Brandwijk; M S Heres; H W Berendse; K D van Dijk; F Lobbezoo
Journal:  Clin Oral Investig       Date:  2020-09-12       Impact factor: 3.573

9.  Motor Cortex Stimulation Reversed Hypernociception, Increased Serotonin in Raphe Neurons, and Caused Inhibition of Spinal Astrocytes in a Parkinson's Disease Rat Model.

Authors:  Ana Carolina P Campos; Miriã B Berzuíno; Gabriela R Barbosa; Helena M R C Freire; Patricia S Lopes; Danielle V Assis; Erich T Fonoff; Rosana L Pagano
Journal:  Cells       Date:  2021-05-11       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.